Fulcrum Therapeutics Inc To Discuss Unmet Need In FSHD, REACH Trial And Key Measures Of Disease Progression Call Transcript
Thank you for joining us today for Fulcrum Therapeutics KOL event on FSHD, a severe progressive and debilitating muscular dystrophy. I'm Naomi Aoki, Fulcrum's Senior Vice President of Corporate Communications and Investor Relations. Before we get started, please be reminded that we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development milestones and financial projections. While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on the obligation to do so. Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of risks, uncertainties associated with our business.
With me on today's call are 2 key opinion leaders, Dr. Nick Johnson and Dr. Jay Han as well as Bryan Stuart, our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
